NCT05521997

Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer

Phase II Study of Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 42 (estimated)
• Sponsor: Washington University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Advanced cervical cancer patients treated with standard of care (SOC) chemoradiation plus glutaminase inhibition with telaglenastat (CB-839) will have increased progression-free survival (PFS) compared to historical rates for patients receiving SOC chemoradiation alone.

Conditions

• Advanced Cervical Carcinoma
• Cervical Cancer
• Cervix Cancer
• Cancer of the Cervix

Interventions

Type	Name	Description
DRUG	Telaglenastat	-800 mg twice per day by mouth
RADIATION	Radiation treatment	* Standard of care * External beam radiation therapy delivered daily 4 days a week and 1 day per week of brachytherapy.
DRUG	Cisplatin	* Standard of care * Weekly administration of cisplain

Timeline

• Start date: 2026-07-31
• Primary completion: 2032-10-07
• Completion: 2032-10-07
• First posted: 2022-08-30
• Last updated: 2026-03-13

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study